Eagle Boston Investment Management Inc. Has $8.67 Million Holdings in Mednax, Inc (MD)
Eagle Boston Investment Management Inc. raised its stake in Mednax, Inc (NYSE:MD) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195,719 shares of the company’s stock after acquiring an additional 4,083 shares during the period. Eagle Boston Investment Management Inc. owned approximately 0.21% of Mednax worth $8,666,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. State of Alaska Department of Revenue increased its stake in shares of Mednax by 6.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 4,393 shares of the company’s stock valued at $265,000 after purchasing an additional 257 shares during the last quarter. Mn Services Vermogensbeheer B.V. grew its position in Mednax by 527.2% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock worth $919,000 after acquiring an additional 12,800 shares during the last quarter. LS Investment Advisors LLC grew its position in Mednax by 15.6% during the 2nd quarter. LS Investment Advisors LLC now owns 6,981 shares of the company’s stock worth $421,000 after acquiring an additional 940 shares during the last quarter. State Treasurer State of Michigan grew its position in Mednax by 0.5% during the 2nd quarter. State Treasurer State of Michigan now owns 38,300 shares of the company’s stock worth $2,312,000 after acquiring an additional 200 shares during the last quarter. Finally, Longview Partners Guernsey LTD grew its position in Mednax by 10.3% during the 2nd quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock worth $303,267,000 after acquiring an additional 467,845 shares during the last quarter. 96.44% of the stock is owned by hedge funds and other institutional investors.
Mednax, Inc (NYSE MD) opened at $49.10 on Friday. The stock has a market capitalization of $4,598.46, a PE ratio of 15.02, a PEG ratio of 1.58 and a beta of 0.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. Mednax, Inc has a 52 week low of $40.56 and a 52 week high of $72.13.
Mednax (NYSE:MD) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.87. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The company had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. During the same period in the previous year, the business earned $1.09 EPS. The firm’s revenue was up 4.9% compared to the same quarter last year. sell-side analysts predict that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on MD. Citigroup Inc. reduced their price objective on Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Robert W. Baird lifted their target price on Mednax from $47.00 to $48.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $44.00 target price on shares of Mednax in a report on Friday, November 3rd. KeyCorp set a $51.00 target price on Mednax and gave the stock a “buy” rating in a report on Wednesday, November 1st. Finally, BMO Capital Markets started coverage on Mednax in a report on Monday, October 16th. They set a “market perform” rating and a $46.00 target price on the stock. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. Mednax presently has a consensus rating of “Hold” and a consensus price target of $54.50.
In related news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/eagle-boston-investment-management-inc-has-8-67-million-holdings-in-mednax-inc-md/1727495.html.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.